Moderna’s mRNA products are designed for high protein expression, beginning with the design of the mRNA itself and including the process used to make the final material.
Our mRNA is made with modified chemistry, replacing the uridine nucleoside found in mammalian mRNA with N1-methylpseudouridine (N1mψ), naturally found in transfer RNA (tRNA), to evade the host innate immune response mechanisms.
The open reading frame (ORF) of the mRNA is codon optimized in our Design Studio using artificial intelligence to improve translational efficiency.
Our 5’ and 3’ UTR sequences, cap1, and polyA tail are engineered to improve stability and translational efficiency of the mRNA.
The mRNA is manufactured using a process specifically designed for vaccine products, minimizing process and product-related impurities such as double-stranded RNA and aborted transcripts.